Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Research & Development: ¥4,172 Mil (TTM As of Mar. 2026)


SHSE:600196 Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
76 GF Score
Price ¥22.62
GF Value ¥27.07
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Research & Development?

Shanghai Fosun Pharmaceutical (Group) Co SHSE:600196 +6.65% 76 Research & Development is ¥4,172 Mil as of Mar. 2026. GuruFocus rates SHSE:600196 with a GF Score™ of 76/100 and a GF Value™ of ¥27.07 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Fosun Pharmaceutical (Group) Co's Research & Development for the three months ended in Mar. 2026 was ¥897 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥4,172 Mil.

Shanghai Fosun Pharmaceutical (Group) Co  (SHSE:600196) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Fosun Pharmaceutical (Group) Co Research & Development Related Terms

Shanghai Fosun Pharmaceutical (Group) Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Research & Development Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,837.30 4,302.09 4,346.05 3,644.36 4,012.56

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 737.45 979.21 1,012.86 1,283.04 896.79
SHSE:600196
76GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4,172 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥4,172 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a Research & Development of ¥4,172 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Research & Development too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Research & Development is ¥4,172 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Research & Development compare to ZTS and UTHR?
Shanghai Fosun Pharmaceutical (Group) Co's Research & Development of ¥4,172 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Research & Development is ¥4,172 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.07, compared to a current price of ¥22.62 — trading 16.4% below its estimated fair value. The current Research & Development is ¥4,172 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current Research & Development is ¥4,172 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of ¥22.62 is trading 16.4% below its estimated GF Value™ of ¥27.07. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SHSE:600196:

  • Research & Development: ¥4,172 Mil
  • GF Value™: ¥27.07 vs. price of ¥22.62 (16.4% below fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score

Get the complete analysis for SHSE:600196

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥22.62
Price
¥27.07
GF Value